Cantor Fitzgerald Remains Bullish on Perrigo (PRGO) Despite Guidance Cut
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Perrigo Co. (PRGO) PT Lowered to $67 at RBC Capital
August 10, 2018 9:07 AM EDTRBC Capital lowered its price target on Perrigo Co. (NYSE: PRGO) to $67.00 (from $89.00) while maintaining a Sector Perform rating.
... MorePerrigo (PRGO) Tops Q2 EPS by 3c, FY EPS Guidance Misses Views
August 9, 2018 6:19 AM EDTPerrigo (NYSE: PRGO) reported Q2 EPS of $1.22, $0.03 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.23 billion.
GUIDANCE:
Perrigo sees FY2018 EPS of $4.75-$4.95, versus the consensus of $5.20.
For earnings history and earnings-related data on Perrigo (PRGO) click here.
... MorePerrigo (PRGO) to Separate Prescription Pharmaceuticals Business
August 9, 2018 6:17 AM EDTPerrigo Company plc (NYSE: PRGO) today announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals (Rx) business following the Company's previously announced strategic portfolio review. Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of differentiated generic pharmaceutical products and allows Perrigo to focus on expanding its leading consumer business. The Board will consider all value-enhancing options, including a possible tax-efficient separation to shareholders, a sale or... More
Perrigo plans to separate prescription pharma business
August 9, 2018 1:04 AM EDTBy Tamara Mathias
(Reuters) - Perrigo Co Plc (NYSE: PRGO) said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker's shares down about 8 percent.
Generic drugmakers such as Perrigo, Mylan (NASDAQ: MYL) and Teva Pharmaceutical Industries (NYSE: TEVA) have suffered over the past few years as price erosion has pressured... More
